Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Loteprednol Etabonate

FDA-approved product (suspension/drops, ophthalmic), marketed as Alrex, Eysuvis, Inveltys and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Loteprednol Etabonate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Anterior uveitis
  • Dry eye syndrome
  • Eye inflammation
  • Inflammation

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Loteprednol Etabonate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Loteprednol Etabonate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection

    NCT01721694 · start 2012-12

    Registered record
    Registry ID
    NCT01721694
    Conditions
    Ocular Inflammation; Infection Associated Blepharitis; Keratitis; Conjunctivitis, Bacterial
    Interventions
    azithromycin 1.5%/Loteprednol 0,5% + placebo; azithromycin 1.5% + Loteprednol 0,5% (separately)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-12
    Completion
    2013-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Inflammation; Infection Associated Blepharitis; Keratitis; Conjunctivitis, Bacterial
    Interventionazithromycin 1.5%/Loteprednol 0,5% + placebo; azithromycin 1.5% + Loteprednol 0,5% (separately)
    PhasePhase 3
    Registry statusWithdrawn

  • Efficacy of Loteprednol Ointment Following Eyelid Surgery

    NCT01749241 · start 2012-09

    Registered record
    Registry ID
    NCT01749241
    Conditions
    Post-operative Healing Following Blepharoplasty and Ptosis Repair
    Interventions
    Loteprednol etabonate ophthalmic ointment; Vehicle Ophthalmic Ointment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2012-09
    Completion
    2015-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-operative Healing Following Blepharoplasty and Ptosis Repair
    InterventionLoteprednol etabonate ophthalmic ointment; Vehicle Ophthalmic Ointment
    PhaseNot applicable
    Registry statusWithdrawn

  • Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

    NCT01456780 · start 2011-08

    Registered record
    Registry ID
    NCT01456780
    Conditions
    Meibomian Gland Dysfunction; Posterior Blepharitis
    Interventions
    Loteprednol/tobramycin; Loteprednol; B+L Advanced Eye Relief Lubricant Drop
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-08
    Completion
    2017-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeibomian Gland Dysfunction; Posterior Blepharitis
    InterventionLoteprednol/tobramycin; Loteprednol; B+L Advanced Eye Relief Lubricant Drop
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%

    NCT01695668 · start 2011-08

    Registered record
    Registry ID
    NCT01695668
    Conditions
    Dry Eyes
    Interventions
    Lotemax; Restasis
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-08
    Completion
    2015-02
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eyes
    InterventionLotemax; Restasis
    PhaseNot applicable
    Registry statusCompleted

  • Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery

    NCT01344226 · start 2011-04

    Registered record
    Registry ID
    NCT01344226
    Conditions
    Pseudophakia; Inflammation
    Interventions
    loteprednol 0.5% ophthalmic solution
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-04
    Completion
    2013-09
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPseudophakia; Inflammation
    Interventionloteprednol 0.5% ophthalmic solution
    PhaseNot recorded
    Registry statusCompleted

  • Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification

    NCT01193504 · start 2010-09

    Registered record
    Registry ID
    NCT01193504
    Conditions
    Pseudophakia; Cataract Surgery
    Interventions
    Pred Forte; Lotemax
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2010-09
    Completion
    2012-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPseudophakia; Cataract Surgery
    InterventionPred Forte; Lotemax
    PhasePhase 4
    Registry statusUnknown

  • Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

    NCT01435460 · start 2010-08

    Registered record
    Registry ID
    NCT01435460
    Conditions
    Seasonal Allergic Conjunctivitis
    Interventions
    Loteprednol etabonate 0.2%; Olopatadine 0.1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-05
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeasonal Allergic Conjunctivitis
    InterventionLoteprednol etabonate 0.2%; Olopatadine 0.1%
    PhasePhase 3
    Registry statusCompleted

  • A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery

    NCT01384266 · start 2010-05

    Registered record
    Registry ID
    NCT01384266
    Conditions
    Intraocular Inflammation
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-05
    Completion
    2011-11
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntraocular Inflammation
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge

    NCT01107405 · start 2010-04

    Registered record
    Registry ID
    NCT01107405
    Conditions
    Allergic Conjunctivitis
    Interventions
    Loteprednol etabonate base (QD); Loteprednol etabonate base (BID); Loteprednol etabonate base (QID); Loteprednol etabonate suspension; Vehicle of loteprednol etabonate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-08
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Conjunctivitis
    InterventionLoteprednol etabonate base (QD); Loteprednol etabonate base (BID); Loteprednol etabonate base (QID); Loteprednol etabonate suspension +1 more
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

    NCT01060072 · start 2010-02

    Registered record
    Registry ID
    NCT01060072
    Conditions
    Inflammation; Pain
    Interventions
    Loteprednol etabonate; Vehicle of Loteprednol Etabonate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-02
    Completion
    2010-10
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation; Pain
    InterventionLoteprednol etabonate; Vehicle of Loteprednol Etabonate
    PhasePhase 3
    Registry statusCompleted

  • Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

    NCT01010633 · start 2009-11

    Registered record
    Registry ID
    NCT01010633
    Conditions
    Inflammation; Pain
    Interventions
    Vehicle of Loteprednol Etabonate; Loteprednol Etabonate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-08
    Enrolment
    406

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation; Pain
    InterventionVehicle of Loteprednol Etabonate; Loteprednol Etabonate
    PhasePhase 3
    Registry statusCompleted

  • Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis

    NCT01028027 · start 2009-10

    Registered record
    Registry ID
    NCT01028027
    Conditions
    Conjunctivitis; Keratitis; Blepharitis
    Interventions
    Loteprednol and tobramycin; Tobramycin and dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-10
    Completion
    2010-03
    Enrolment
    357

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConjunctivitis; Keratitis; Blepharitis
    InterventionLoteprednol and tobramycin; Tobramycin and dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • Use of Loteprednol for Contact Lens Intolerance and Dryness

    NCT00817557 · start 2009-01

    Registered record
    Registry ID
    NCT00817557
    Conditions
    Contact Lenses Dryness
    Interventions
    Loteprednol; Rewetter
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-01
    Completion
    2009-09
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContact Lenses Dryness
    InterventionLoteprednol; Rewetter
    PhasePhase 4
    Registry statusUnknown

  • Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis

    NCT00705159 · start 2008-06

    Registered record
    Registry ID
    NCT00705159
    Conditions
    Conjunctivitis
    Interventions
    loteprednol etabonate and tobramycin; loteprednol etabonate; Tobramycin; Vehicle of Zylet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-06
    Completion
    2010-05
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConjunctivitis
    Interventionloteprednol etabonate and tobramycin; loteprednol etabonate; Tobramycin; Vehicle of Zylet
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

    NCT00689078 · start 2008-05

    Registered record
    Registry ID
    NCT00689078
    Conditions
    Allergic Conjunctivitis
    Interventions
    Prednisolone Acetate 1%; Prednisolone Acetate 0.12%; Loteprednol Etabonate 0.2%; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    2008-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Conjunctivitis
    InterventionPrednisolone Acetate 1%; Prednisolone Acetate 0.12%; Loteprednol Etabonate 0.2%; Placebo
    PhasePhase 4
    Registry statusCompleted